Retrospective evaluation of risk factors for worsening renal function after angiotensin‐converting enzyme inhibitor treatment in dogs

Abstract Background Angiotensin‐converting enzyme inhibitors (ACEi) have the potential to cause worsening renal function (WRF). Therefore, reevaluation of renal function is recommended 1‐2 weeks after starting ACEi therapy. Objectives To identify risk factors for WRF in dogs receiving ACEi for cardi...

Full description

Saved in:
Bibliographic Details
Main Authors: Yelim Lee, Minju Baek, Dongseop Lee, Jinyeong Park, Yeon Chae, Byeong‐Teck Kang, Taesik Yun, Hakhyun Kim
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Journal of Veterinary Internal Medicine
Subjects:
Online Access:https://doi.org/10.1111/jvim.17252
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832584162083602432
author Yelim Lee
Minju Baek
Dongseop Lee
Jinyeong Park
Yeon Chae
Byeong‐Teck Kang
Taesik Yun
Hakhyun Kim
author_facet Yelim Lee
Minju Baek
Dongseop Lee
Jinyeong Park
Yeon Chae
Byeong‐Teck Kang
Taesik Yun
Hakhyun Kim
author_sort Yelim Lee
collection DOAJ
description Abstract Background Angiotensin‐converting enzyme inhibitors (ACEi) have the potential to cause worsening renal function (WRF). Therefore, reevaluation of renal function is recommended 1‐2 weeks after starting ACEi therapy. Objectives To identify risk factors for WRF in dogs receiving ACEi for cardiac diseases, proteinuria, or systemic hypertension. Animals A total of 156 client‐owned dogs that received ACEi were included. Methods Serum creatinine concentration was determined at the initial presentation and first reevaluation to detect and grade WRF (increase in sCr ≥ 0.3 mg/dL). Grade 1 (nonazotemic), 2 (mild), and 3 (moderate to severe) WRF were characterized by sCr remaining ≤1.6 mg/dL, 1.7‐2.5 mg/dL increase, and 2.6‐5.0 mg/dL increase, respectively. Demographic and serum chemistry data, such as total protein, albumin, blood urea nitrogen, creatinine, symmetric dimethylarginine, glucose, triglyceride, total cholesterol concentrations, and serum electrolyte concentrations at first presentation, were evaluated. Multivariable modeling was performed to identify risk factors for WRF after treatment with ACEi. Results Worsening renal function was identified in 27/156 (17%, 95% confidence interval [CI], 0.11‐0.23) dogs after ACEi treatment. It was classified as Grades 1, 2, and 3 in 17, 2, and 8 dogs, respectively. The only significant factors associated with WRF in dogs receiving ACEi were concurrent administration of furosemide (odds ratio, 5.05; 95% CI, 2.05‐12.4; P < .001) and pre‐existing azotemia (odds ratio, 3.21; 95% CI, 1.28‐8.03; P = .01). Conclusions and Clinical Importance Although WRF is uncommon and mild, ACEi should be cautiously prescribed in dogs receiving furosemide or those with pre‐existing azotemia.
format Article
id doaj-art-283c1e388b004f39a70ad942e539a812
institution Kabale University
issn 0891-6640
1939-1676
language English
publishDate 2025-01-01
publisher Wiley
record_format Article
series Journal of Veterinary Internal Medicine
spelling doaj-art-283c1e388b004f39a70ad942e539a8122025-01-27T15:22:40ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762025-01-01391n/an/a10.1111/jvim.17252Retrospective evaluation of risk factors for worsening renal function after angiotensin‐converting enzyme inhibitor treatment in dogsYelim Lee0Minju Baek1Dongseop Lee2Jinyeong Park3Yeon Chae4Byeong‐Teck Kang5Taesik Yun6Hakhyun Kim7Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine Chungbuk National University Cheongju 28644 Republic of KoreaLaboratory of Veterinary Internal Medicine, College of Veterinary Medicine Chungbuk National University Cheongju 28644 Republic of KoreaLaboratory of Veterinary Internal Medicine, College of Veterinary Medicine Chungbuk National University Cheongju 28644 Republic of KoreaLaboratory of Veterinary Internal Medicine, College of Veterinary Medicine Chungbuk National University Cheongju 28644 Republic of KoreaLaboratory of Veterinary Internal Medicine, College of Veterinary Medicine Chungbuk National University Cheongju 28644 Republic of KoreaLaboratory of Veterinary Internal Medicine, College of Veterinary Medicine Chungbuk National University Cheongju 28644 Republic of KoreaLaboratory of Veterinary Internal Medicine, College of Veterinary Medicine Chungbuk National University Cheongju 28644 Republic of KoreaLaboratory of Veterinary Internal Medicine, College of Veterinary Medicine Chungbuk National University Cheongju 28644 Republic of KoreaAbstract Background Angiotensin‐converting enzyme inhibitors (ACEi) have the potential to cause worsening renal function (WRF). Therefore, reevaluation of renal function is recommended 1‐2 weeks after starting ACEi therapy. Objectives To identify risk factors for WRF in dogs receiving ACEi for cardiac diseases, proteinuria, or systemic hypertension. Animals A total of 156 client‐owned dogs that received ACEi were included. Methods Serum creatinine concentration was determined at the initial presentation and first reevaluation to detect and grade WRF (increase in sCr ≥ 0.3 mg/dL). Grade 1 (nonazotemic), 2 (mild), and 3 (moderate to severe) WRF were characterized by sCr remaining ≤1.6 mg/dL, 1.7‐2.5 mg/dL increase, and 2.6‐5.0 mg/dL increase, respectively. Demographic and serum chemistry data, such as total protein, albumin, blood urea nitrogen, creatinine, symmetric dimethylarginine, glucose, triglyceride, total cholesterol concentrations, and serum electrolyte concentrations at first presentation, were evaluated. Multivariable modeling was performed to identify risk factors for WRF after treatment with ACEi. Results Worsening renal function was identified in 27/156 (17%, 95% confidence interval [CI], 0.11‐0.23) dogs after ACEi treatment. It was classified as Grades 1, 2, and 3 in 17, 2, and 8 dogs, respectively. The only significant factors associated with WRF in dogs receiving ACEi were concurrent administration of furosemide (odds ratio, 5.05; 95% CI, 2.05‐12.4; P < .001) and pre‐existing azotemia (odds ratio, 3.21; 95% CI, 1.28‐8.03; P = .01). Conclusions and Clinical Importance Although WRF is uncommon and mild, ACEi should be cautiously prescribed in dogs receiving furosemide or those with pre‐existing azotemia.https://doi.org/10.1111/jvim.17252angiotensin‐converting enzyme inhibitorazotemiafurosemidekidney injury
spellingShingle Yelim Lee
Minju Baek
Dongseop Lee
Jinyeong Park
Yeon Chae
Byeong‐Teck Kang
Taesik Yun
Hakhyun Kim
Retrospective evaluation of risk factors for worsening renal function after angiotensin‐converting enzyme inhibitor treatment in dogs
Journal of Veterinary Internal Medicine
angiotensin‐converting enzyme inhibitor
azotemia
furosemide
kidney injury
title Retrospective evaluation of risk factors for worsening renal function after angiotensin‐converting enzyme inhibitor treatment in dogs
title_full Retrospective evaluation of risk factors for worsening renal function after angiotensin‐converting enzyme inhibitor treatment in dogs
title_fullStr Retrospective evaluation of risk factors for worsening renal function after angiotensin‐converting enzyme inhibitor treatment in dogs
title_full_unstemmed Retrospective evaluation of risk factors for worsening renal function after angiotensin‐converting enzyme inhibitor treatment in dogs
title_short Retrospective evaluation of risk factors for worsening renal function after angiotensin‐converting enzyme inhibitor treatment in dogs
title_sort retrospective evaluation of risk factors for worsening renal function after angiotensin converting enzyme inhibitor treatment in dogs
topic angiotensin‐converting enzyme inhibitor
azotemia
furosemide
kidney injury
url https://doi.org/10.1111/jvim.17252
work_keys_str_mv AT yelimlee retrospectiveevaluationofriskfactorsforworseningrenalfunctionafterangiotensinconvertingenzymeinhibitortreatmentindogs
AT minjubaek retrospectiveevaluationofriskfactorsforworseningrenalfunctionafterangiotensinconvertingenzymeinhibitortreatmentindogs
AT dongseoplee retrospectiveevaluationofriskfactorsforworseningrenalfunctionafterangiotensinconvertingenzymeinhibitortreatmentindogs
AT jinyeongpark retrospectiveevaluationofriskfactorsforworseningrenalfunctionafterangiotensinconvertingenzymeinhibitortreatmentindogs
AT yeonchae retrospectiveevaluationofriskfactorsforworseningrenalfunctionafterangiotensinconvertingenzymeinhibitortreatmentindogs
AT byeongteckkang retrospectiveevaluationofriskfactorsforworseningrenalfunctionafterangiotensinconvertingenzymeinhibitortreatmentindogs
AT taesikyun retrospectiveevaluationofriskfactorsforworseningrenalfunctionafterangiotensinconvertingenzymeinhibitortreatmentindogs
AT hakhyunkim retrospectiveevaluationofriskfactorsforworseningrenalfunctionafterangiotensinconvertingenzymeinhibitortreatmentindogs